StreetInsider.com News Articles

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

Tue, 25 Feb 2025 06:35:00 -0400

Cash runway is extended from Q1 to H2 2026 with approximately €46 million (PLN 192 million) in cash and other financial assets held by Ryvu as of February 23, 2025. In addition, the company has secured approximately €22 million (PLN 91 million) in non-dilutive grant funding.
Ryvu's workforce will be reduced by approximately 30%.
Three Phase II RVU120 studies are in progress as planned: RIVER-81 (combination with venetoclax in AML), POTAMI-61 (monotherapy/combination with ruxolitinib in myelofibrosis), and REMARK (monotherapy in LR-MDS).
The Phase II RIVER-52 study of RVU120 monotherapy in patients with AML or HR-MDS, will not enroll new patients to focus

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

- 2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics provides an update on RVU120 Phase II program

Thu, 12 Dec 2024 05:30:00 -0400

KRAKOW, Poland, Dec. 12, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its fully-owned first-in-class dual CDK8/19 inhibitor, currently being developed to treat hematologic malignancies.

Paweł Przewięźlikowski, co-founder and Chief Executive Officer of Ryvu Therapeutics said:

-          2024 has been transformative for RVU120 development plan in hematologic malignancies, marked by activating over 100 clinical sites across Europe

Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)

Thu, 05 Dec 2024 08:00:00 -0400

The primary goal of the study is to evaluate the safety and efficacy of RVU120 in patients with myelofibrosis (MF), both as a single agent and in combination with ruxolitinib (RUX).
The study was launched based on RVU120's activity in the RIVER-51 Phase I study in patients with acute myeloid leukemia (AML) and translational data generated in MF.
KRAKOW, Poland, Dec. 5, 2024 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the first patient had